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Abstract
An initial course of standard heparin (SH) or low-molecular-weight heparins (LMWH) is regarded as the treatment of 
choice for patients with deep venous thrombosis (DVT). LMWH have better bioavailability after subcutaneous administra­
tion, have a longer half-life, and show higher and more predictable anticoagulant activity. As a result they can be given 
subcutaneously and without laboratory control, using a dose that is determined by body weight. Because of these multiple 
advantages of LMWH they will replace SH in the future and subsequently home treatment with LMWH of selected patients 
seems feasible. The currently accepted approach is to start with SH or LMWH therapy combined with oral anticoagulant 
therapy (OAT) at the time of diagnosis. The course of SH or LMWH should continue for at least 5 days, provided that 
international normalized ratio (INR) is in the therapeutic range on 2 consecutive days. OAT should be continued for at least 
3 months to prolong the prothrombin time to an INR of 2 -3 . When oral anticoagulants are either contraindicated or 
inconvenient, SH or LMWH can be used at the middosing interval. The role of anti-platelet treatment is not yet established
4
and should be compared with coumarin therapy in the future.
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1. Introduction
Deep venous thrombosis (DVT) is a potentially 
fatal disorder if untreated. The aims of treating pa­
tients with DVT are prevention of death from pul­
monary embolism, reduction of morbidity caused by 
thrombus extension and prevention of the post- 
thrombotic syndrome (PTS). Prior to the late 1930s,
* Corresponding author. Tel.: ( + 31-243) 614782; fax: ( + 31- 
243) 543714.
patients with DVT were treated with bedrest alone. 
Heparin became available in a clinically usable form 
in 1935. Dicoumarol became available in 1940. The 
last two decades the approach to the diagnosis of 
DVT has changed radically and new developments 
of treatment have occurred [I]. Since accurate diag­
nostic tools for detection of DVT, like venography, 
compression ultrasound and plethysmography be­
came available, it has been possible to perform 
randomized clinical trials to evaluate the various 
approaches for prevention and treatment of venous
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thrombosis [2]. These trials have resolved some of 
the uncertainties that a clinician confronts in select­
ing appropriate anticoagulant therapy. Furthermore, 
new therapeutic agents, like low-molecular-weight 
heparins, have been introduced and improved dosage 
regimens have been developed for established drugs.
In the following the current literature dealing with
«
the initial and long-term treatment of DVT is re­
viewed. Although in practice heparin and oral antico­
agulants are administered together, they will be dis­
cussed separately.
2. Initial treatment
2.L Standard unfractionated heparin (SH)
SH has generally been considered the antithrom­
botic drug of choice for the initial treatment of DVT 
because of its immediate anticoagulant effect [3]. 
This approach has been supported by a randomized 
double-blind study by Brandjes et ai. [4]: the efficacy 
and safety of continuous inU*avenous SH plus aceno- 
coumarol were compared to treatment with aceno- 
coumarol alone in the initial treatment of proximal 
DVT. This study was terminated prematurely be­
cause of an excessive number of symptomatic throm­
botic events in the group that received aceno- 
coumarol alone (20% as compared with 6.7% in the 
group that received both).
SH acts mainly by binding to and enhancing the 
effect of antithrombin III, which results in a rapid 
inhibition of a number of serine proteinases, notably 
thrombin (factor Ila), factor IXa and factor Xa [5,6]. 
When administered intravenously as a bolus, SH has 
an effective concentration-dependent half-life of 
about 1^ hours.
When SH is given in therapeutic doses, its anti­
coagulant effect must be monitored and if necessary 
the dosage should be adjusted, because of a wide 
interindividual variability in pharmacodynamics. 
Clinically effective treatment depends on the inten­
sity of the SH anticoagulant effect as measured by 
daily laboratory tests, like activated partial thro mo- 
plastin time (APTT) or heparin level. APTT is the 
most commonly used laboratory test to monitor SH 
therapy, although it is not specific for heparin. APTT 
is sensitive to the inhibitory effects of SH on throm­
bin, factor Xa and factor IXa. In clinical practice SH 
is adjusted to maintain the APTT response between 
an (empirically stated) therapeutic range—i.e., 1.5 
and 2.5 times the control value, which is equivalent 
to a heparin level of 0.2 to 0.4 U /m l by protamine 
titration [7,8]. For this purpose a nomogram has been 
developed which results in achieving a therapeutic 
APTT at 24 and 48 h in a large proportion of 
patients and in reduced periods of inadequate antico- 
agulation during SH therapy [9]. It should be noted 
that the different commercial APTT reagents vary in 
their responsiveness to SH, so this nomogram is not 
applicable to all APTT systems but should be adapted 
by the local laboratory [10].
For this reason some hospitals monitor heparin 
level by a chromogenic substrate assay according to 
Teien [11] instead of APTT. This assay allows an 
accurate reading within a rather broad range, in 
contrast to APTT, the reproducibility of which de­
creases with increasing clotting times [12,13]. Also 
the chromogenic assay is more specific for the hep­
arin level. To demonstrate the value of this chro­
mogenic assay in monitoring heparin therapy, it 
should be compared to APTT. These studies have 
not yet been performed.
Prospective trials have indicated that failure to 
exceed the lower limit of the therapeutic range is 
associated with an unacceptably high rate of recur­
rent venous thromboembolism [14,15]. Hull et al. 
observed that the relative risk of recurrent venous 
thrombotic events was 15 times higher in patients in 
whom the APTT remained subtherapeutic during the 
first 24 h or more of SH therapy than in those 
patients with a therapeutic APTT [14]. Basu et al. 
observed that the relative risk of recurrent throm­
botic events was 7 times higher in patients in whom 
APTT was less than 50 s for 2 consecutive days than 
in patients with therapeutic APTT results [15]. The 
relationship between bleeding complications and ‘ex­
cessive’ APTT is not clear. One study even demon­
strated no association between APTT above the ther­
apeutic range and bleeding [16].
A rapid therapeutic effect of SH is achieved by 
commencing with a loading dose of 5000 U as an 
intravenous bolus followed by continuous infusion of 
1000-1250 U /h . APTT should be performed at 
approximately 6 h after the bolus and the SH dose 
adjusted to the result obtained. In case APTT is
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subtherapeutic, it should be repeated 6 h after in­
creasing the SH dose to optimize the therapy.
A controversial issue in the treatment of DVT is 
the optima! mode of SH administration. SH is not 
absorbed after oral administration and therefore 
should be given by intravenous injection, intermittent 
or continuous. Intramuscular injection can produce 
large haematomas and should be avoided. A random­
ized comparison showed that continuous intravenous 
SH infusion is safer than intermittent intravenous SH 
injections, because the latter was associated with 
more bleeding complications, whereas both showed 
similar efficacy in preventing recurrent thrombosis
[17]. The disadvantages of continuous SH infusion 
include hospitalization, prolonged immobilization 
and a possible increase in the cost of treatment.
These disadvantages might be overcome if SH 
could be administered effectively and safely using 
the subcutaneous route. Studies comparing intra­
venous to subcutaneous administration are contradic­
tory. A meta-analysis of the most important studies 
indicated that unfractionated SH administered subcu- 
taneously twice daily is more effective and at least as 
safe as continuous intravenous SH administration
[18]. This is in contrast to a trial performed by Hull 
et al. in which subcutaneous SH resulted in a higher 
frequency of recurrent thrombosis [19].
2.2. Low molecular weight heparins (LMWH)
LMWH are an important new class of anticoagu­
lants which have revolutionized the standard care of 
DVT [20]. LMWH are fragments of heparin, pro­
duced by either chemical or enzymatic depolymeri­
zation. The mean molecular weight is 4000-5000 Da 
(the molecular weight of heparin is 25 000 Da).
In pharmacokinetic studies it was shown that the 
peak anti~Xa and anti-IIa activity appeared after 3 h 
and that the effect was sustained for at least 12 h and 
gradually disappeared by 24 h. The intra-individual 
variation between two administrations was small [21]. 
The comparing resorption as calculated from anti-Xa
activity over an ascending dosage range of several 
LMWH was linear [22]. Most studies showed a 
relatively more anti-Xa than anti-IIa activity [23,24]. 
It should be noted that these studies used low doses 
of LMWH [25,26]. Recently Agnelli et al. assessed 
anti-IIa activity with a more sensitive assay. They 
compared the relative half-lives of prophylactic and
therapeutic doses of LMWH by assessing both anti- 
IIa and anti-Xa activity. In contrast to the other 
studies, which reported a low half-life of the anti-IIa 
activity, they found that a high and sustained plasma 
anti-IIa activity was achieved when LMWH were 
administered in therapeutic doses used in contempo­
rary trials with only a moderate prolongation of the
APTT [27].
LMWH have a number of advantages over SH: 
because there is less protein binding of LMWH [28], 
they have a more predictable anticoagulant response 
when administered in fixed doses, so the dose only 
has to be adjusted to the patient’s body weight. Also 
LMWH have a longer plasma half-life [29,30] and a 
more favourable antithrombotic to haemorrhagic risk 
ratio; they maintain their antithrombotic effect prob­
ably through anti-Xa activity but cause less clinical 
bleeding by a reduced action on the APTT and 
overall clotting [28,31,32]. These properties might 
allow LMWH to be administered once daily without 
laboratory monitoring. The final advantage is early 
mobilization, because the patient is not hindered by 
an infusion pump.
LMWH administered in a fixed dose by subcuta­
neous injection have been compared with dose-ad­
justed SH administered by continuous infusion in 
several studies. In these studies two different out­
come assessments were used. First, the change in 
thrombus size was assessed by repeating venography 
at the end of the course of treatment [33-37]: LMWH 
were as effective as SH. Second, most studies used 
the occurrence of the symptomatic recurrent DVT as 
end-point; there was a strong trend for LMWH to be 
more effective and safer than SH [38-41]. Two 
meta-analyses of these trials found similar trends 
indicating improved efficacy and safety with LMWH 
[42,43], It is uncertain if the favorable outcomes of 
treatment with different LMWH can be extrapolated 
to ail other types of LMWH [24,42,44], Also it is not 
certain whether there is bioequivalence between all 
products. As a consequence similar studies with 
different types of LMWH should be performed. Fi­
nally it should be noted that only a few studies used 
a once-daily regimen of LMWH [39,41,45], the other 
studies twice daily. Currently LMWH once versus 
twice daily are being compared. Table 1 shows the 
different LMWH that are currently registered for 
treatment of DVT in the Netherlands.
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Table 1
LMWH that are registered for treatment of DVT in the Nether­
lands
Generic name Trade name Company Dosage
Dalteparine Fragmin Pharmacia 200 iU /k g
Hnoxaparine Clexane Rhône-Poulenc Rorer 1 mg/kg
Nadroparine Fraxiparine Sanofi 225 IV /k g
LMWH = low-molecular-weight heparin; DVT — deep venous
thrombosis.
Jn conclusion, LMWH seem promising for the 
initial treatment of DVT and are about to replace 
intravenous heparin treatment [20], Recently evi­
dence has been provided that in the future patients 
with DVT might even be treated with LMWH at 
home [46,47], Both studies compared treatment with 
SH (administered in the hospital intravenously) to 
LMWH. The studies allowed outpatients taking 
LMWH to go home immediately and hospitalized 
patients taking LMWH to be discharged early. End­
points of the studies were recurrent DVT, major 
bleeding, quality of life and costs. Levine et al. 
treated 253 patients with SH and 247 patients with 
LMWH (1 mg enoxaparin per kg body weight subcu­
taneo usly twice daily) [46]. Recurrent DVT occurred 
in respectively 6.7 and 5.3%, major bleeding in 1 
and 2%. Koopman et al. treated 198 patients with SH 
and 202 patients with LMWH (nadroparine-Ca, dose 
adjusted to bodyweight) [47]. Recurrent DVT oc­
curred in respectively 8.7 and 6.9%, major bleeding 
in 2 and 0.5%. In this study improvements in quality 
of life were similar in both groups, the LMWH 
recipients even having better physical and social 
function. Both studies showed a similar frequency of 
recurrent tromboembolic events and bleeding com­
plications. In conclusion treatment with LMWH at 
home seems feasible, effective and safe [46-48]. 
This change from hospital to community care might 
overlook two important achievements of recent years. 
First objective diagnostic testing should be per­
formed in every patient to avoid under- or overtreat­
ment, Secondly, each patient should get size-to-fit 
compression stockings to prevent the post-thrombo­
tic syndrome.
2.3. Du ration of initial treatment
A consensus about the optimal duration of initial 
treatment in patients with DVT has not been 
achieved. According to the conventional approach 
SH was given for 10 days and oral anticoagulant 
therapy was started on days 5 to 10 to ensure an 
overlap period of 4 to 5 days before heparin was 
discontinued. The rationale for this regimen was 
based on observation in animals [49,50]; subsequent 
clinical trials have demonstrated its effectiveness.
Two randomized studies in patients with proximal 
DVT have demonstrated that a short course of SH 
therapy (4 to 5 days) is associated with a recurrence 
rate and bleeding complications similar to a longer 
course (9 to 10 days) [14,51], Such a short course 
reduces the length of hospital stay, which offers a 
substantial financial benefit and may possibly reduce 
the incidence of heparin-induced thrombocytopenia 
or hospital acquired infections.
In most countries a short course of SH or LMWH 
is currently regarded as the standard initial treatment. 
Provided the international normalized ratio (INR) is 
in the therapeutic range on 2 consecutive days, SH or 
LMWH can be discontinued after 5 days. The ques­
tion is whether in the case of extensive thrombosis 
(e.g., iliac vein thrombosis) 5 days of SH therapy is 
also enough; in most trials patients with extensive 
DVT are excluded.
2.4. Side-effects
The major side-effect of heparin therapy is bleed­
ing. Maintaining the APTT within the therapeutic 
range does not guarantee protection from bleeding 
complications. In the case of bleeding, withdrawal of 
heparin is usually sufficient because it is cleared 
rapidly from the plasma with an average half-life of 
90 min. If bleeding continues, protamine sulphate 
infusion will neutralize the heparin effect (1 mg 
protamine neutralizes approximately 150 units of 
heparin). The risk of bleeding is increased with an 
increased heparin dose, but also other factors such as 
recent surgery, trauma, peptic ulcer, malignancy or 
an haemostatic abnormality are important. Most tri­
als comparing SH to LMWH suggest that LMWH
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cause fewer bleeding complications [20,39—41], This embolism despite anticoagulation [8,62,63]. No data
is probably due to a lower anti-IIa/anti-Xa ratio of 
LMWH than of SH.
Another side-effect of SH or LMWH is thrombo­
cytopenia, an allergic reaction [5,38], It typically 
appears 5 or more days after the start of therapy. The 
thrombocytopenia is caused by heparin-dependent 
IgG antibodies that activate platelets through their Fc 
receptors [52], Paradoxically, thrombotic complica­
tions develop in some patients with heparin-induced 
thrombocytopenia, possibly because of in vivo 
platelet activation [53]. With these patients the use of 
danaparoid (a combination of heparan sulphate and 
dennatan sulphate) should be considered [5,54], It 
has been demonstrated that thrombocytopenia occurs 
less in patients treated with LMWH [55]. Other 
adverse reactions including osteoporosis, alopecia, 
local skin necrosis from hypersensitivity and anaphy­
lactic shock are rare.
3. Thrombolysis
In DVT thrombolysis is suggested to prevent 
post-thrombotic symptoms if complete lysis could be 
achieved before valve destruction and recurrent ve­
nous thromboembolic events have occurred. Several 
trials have evaluated thrombolytic therapy. Most of 
them were not able to demonstrate a lower incidence 
of the post-thrombotic syndrome [56-60]. It was 
generally accepted that early thrombolysis improves 
valve function. However, a contentious issue is 
whether thrombolysis will also decrease the long-term 
manifestations of PTS. As this has not so far been 
supported by experimental clinical trials, and be­
cause of a high incidence of major bleeding (2.9 
times higher than in SH therapy) the use of throm­
bolysis can not be propagated as routine treatment 
[57,61]. At present this kind of treatment should be 
restricted to severe cases of DVT like phlegmasia 
cerulea dolens.
4. Vena cava filter
The main reason for placing a vena cavai filter is 
the existence of a contraindication or a severe com­
plication of anticoagulation or recurrent pulmonary
are available comparing the effect of these filters to 
standard anticoagulant treatment, so the exact indica­
tions are unknown.
5. Long-term treatment
5.1, Oral anticoagulant treatment (OAT)
After the initial treatment period with heparin 
there is an obvious need for long-term intensive 
anticoagulant treatment [64]. The rationale for OAT 
is to prevent recurrent thromboembolic episodes and 
possibly to assist the physiological resolution of the 
thrombus. Coumarin derivatives, such as warfarin,
»
acenocoumarol and fenprocoumon are the oral anti­
coagulants of choice [8,65]. An unacceptably high 
recurrence rate occurred if no, too short or too low 
intensity secondary prophylaxis was used [66,67].
Coumarin derivatives are competitive vitamin K 
antagonists and are well absorbed from the gastro­
intestinal tract. They inhibit the vitamin-K-dependent 
carboxylation of coagulant factors II, VII, IX and X 
[49,50] and also of proteins C and S [66].
Coumarin therapy can be commenced on the same 
day as heparin therapy with a maintenance dose or 
with a small loading dose which is approximately 
twice the average maintenance dose. Larger loading 
has no advantage over the smaller loading dose and 
is potentially dangerous, mainly in patients with 
protein C deficiency (skin necrosis).
In the past prothrombin time (PT) was the most 
important laboratory test to monitor coumarin ther­
apy. Because the PT was difficult to standardize a 
calibration model was adopted in 1982 converting 
the PT ratio observed with the local thromboplastin 
into an international normalized ratio (INR). It should 
be noted that there is a wide interlaboratory variation 
in the accuracy of INR determinations [68]. INR 
monitoring is usually performed daily during heparin 
therapy until a stable level is achieved, thereafter it 
may be performed less frequently. It was recently 
demonstrated that it is more difficult to sustain a 
therapeutic INR in patients with a malignancy. More 
frequent monitoring may be needed in these cases to 
achieve a low complication rate [69]. Computer-ad- 
justed dose schemes have also been devised for the
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ontrol of short- and long-term therapy [70]. Evi- 
lenee from recent studies indicates that an effective 
evel of anticoagulation in DVT is reflected by an 
NR of 2.0 to 3.0. It was demonstrated by Hull et al. 
hat it is safe to use a less intense dosage regimen; it 
vas associated with a low frequency of recurrent 
DVT (2%) and a reduced risk of haemorrhage [67]. 
\  more intense range, that might be indicated for 
example in patients with recurrent DVT or thrombo­
sis at an abnormal location (vena cava, portal vein), 
corresponds to an INR of 2.5 to 3.5.
5.2. Low-dose SH or LMWH subcutaneously
In patients who are at risk of developing bleeding, 
LMWH subcutaneously may be an acceptable alter­
native to coumarin [71-73]. Hull et al. compared 
warfarin sodium versus low-dose SH in the long-term 
treatment of DVT. They found adjusted-dose war­
farin sodium more effective than low-dose subcuta­
neous heparin in preventing recurrent DVT, but its 
use was accompanied by a significant risk of bleed­
ing [72]. In the study by Pini et al. LMWH were 
compared with conventional warfarin for 3 months 
[74]. In this period the recurrence rate was not 
significantly different in the two groups. However, 
there was a significant reduction of bleeding compli­
cations in the LMWH group.
Comparison of LMWH with coumarin merits con­
firmation in subsequent studies. To date, secondary 
thromboprophylaxis with subcutaneous heparin has 
not shown advantages over oral anticoagulant ther­
apy, particularly in view of the higher costs, the need 
for administration by injection and the risk of osteo­
porosis.
5,5. Duration o f secondary prophylaxis
Despite investigation in a number of studies over 
the last few decades, the optimal duration of OAT is 
still a matter of debate. For most patients it is 
recommended to be continued for 3 months [8,75]. 
This approach is supported by 2 studies by Hull et al. 
who demonstrated low rates of recurrent thrombosis 
in patients with proximal DVT who received 3 
months of OAT [67,71]. Because it is important to 
minimize the negative side-effects without increasing 
the recurrence rate, shorter durations of OAT have
been evaluated. The results are inconclusive [76-78]. 
Levine et al. compared 4 weeks with 3 months of 
coumarin in patients who had a normal impedance 
plethysmograph (IPG) after 4 weeks. Even after 
normalization of the IPG 8.6% of the placebo group 
developed recurrent thrombosis versus 0.9% of the 
warfarin group. They conclude that even after nor­
malization of the IPG the rate of recurrent DVT after 
stopping OAT after 4 weeks is high [79],
Schulman et al. compared 6 weeks treatment with 
6 months treatment in a large multicentre trial [78]. 
This study demonstrated a benefit of prolonged anti­
coagulation in the 6-month group, although the 
long-term outcome for all patients was discouraging 
since there was no difference in the incidence of 
recurrent events in the two groups during 24 months 
of follow-up after the initial episode.
The duration of OAT should be tailored to the 
individual patient [80]. The most important factor for 
continuing OAT is the existence of risk factors, such 
as inherited thrombophilias, malignancies, mechani­
cal obstruction or prolonged immobilization. In these 
cases OAT should be continued for a longer time. 
More detailed information on this subject is not 
available because there have been no trials published 
comparing a different duration of OAT in these 
groups of patients.
5.4. Side-effects o f oral anticoagulants
The most important adverse effect of oral antico­
agulants is bleeding; it may be mild, such as epis­
taxis or purpura, or more serious like cerebral haem­
orrhage, retroperitoneal bleeding, large haematomas 
or gastrointestinal bleeding. The risk of bleeding is 
directly linked to the intensity of the anticoagulant 
effect: less intensive therapy reduces bleeding com­
plications without loss of clinical benefit when INR 
is above 2 [67].
Coumarin effects can be reversed within 24 h by 
large doses of parenteral vitamin K. The serious and 
life-threatening bleeding requires urgent and imme­
diate correction of INR with prothrombin complex 
after coumarins are stopped.
Another complication associated with the 
coumarins is hepatitis. Finally, thrombosis in the 
microcirculation, causing skin necrosis, may occur. 
This complication occasionally occurs in the first
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weeks of therapy and has been associated with pro­
tein C deficiency and malignancy. The best way to 
avoid it is to commence with a small loading dose.
5.5. Anti-plate let treatment
Anti-platelet treatment, like acetylsalicylic acid, 
dipyridamole and epoprostenol, inhibits platelet ag­
gregation by affecting the balance between prostacy­
clin and thromboxane A2. These kinds of drugs are 
registered for secondary prevention of arterial throm­
bosis (e.g., after myocardial infarction, stroke or 
bypass surgery). It has been shown that long-term 
anti-platelet therapy is feasible and that among pa­
tients at high risk of occlusive vascular disease, it 
reduces the risk of vascular death, myocardial infarc­
tion, stroke and other vascular occlusion. Previously, 
it had generally been concluded that anti-platelet 
prophylaxis had little or no effect on venous throm­
bosis or pulmonary embolism, Recently an overview 
of trials comparing subcutaneous heparin with anti­
platelet therapy in throniboprophylactic studies in 
surgical patients has shown that anti-platelet therapy 
(usually studied for only about 1 to 3 weeks) sub­
stantially reduced the incidence of pulmonary em­
bolism [81,82].
Since anti-platelet therapy seems effective in pre­
venting arterial vascular disease and DVT after 
surgery, one could assume that this therapy might 
also be useful in the long-term treatment of DVT, 
instead of coumarin. Trials comparing these two 
treatments have not been published yet. Advantages 
would be that it is a practicable therapy without the 
use of laboratory monitoring and perhaps with fewer 
bleeding complications (as in thromboprophylaxis 
the risk of bleeding complications seemed to be 
relatively small) [81], At present, anti-platelet ther­
apy should not be recommended for long-term treat­
ment of DVT until controlled, randomized studies 
comparing coumarins with antiplatelets have been 
performed.
and reduced activity of the fibrinolytic system[83]. 
DVT of the lower extremity during pregnancy is 
infrequent, but pulmonary embolism remains an im­
portant cause of maternal mortality. Coumarin 
derivatives and fibrinolytic agents are considered to 
be hazardous in pregnancy. Coumarins cross the 
placenta and may cause spontaneous abortion and 
specific embryopathies if given in the first trimester 
of pregnancy. This risk is said to be greatest between 
the 6th and 9th week of gestation [84], There is also 
concern that they may cause fetal bleeding during 
and after delivery [85], The anticoagulant effect on 
the fetus is more pronounced than in the mother 
because the immature fetal liver produces only low 
levels of vitamin-K-dependent clotting factors and 
the maternal procoagulant factors do not cross the 
placental barrier due to their large molecular size 
[83].
Nevertheless, pregnant women with DVT should 
receive long-term anticoagulation. This is best ac­
complished with heparin or LMWH. A review of the 
published experience of the utilization of LMWH in 
obstetrics and gynaecology revealed that LMWH do 
not cross the placenta in any trimester and there is no 
evidence of any mutagenic and teratogenic effect of 
these drugs [86-88]. When long-term treatment is 
required, patients should be educated to administer 
heparin or LMWH by subcutaneous injections to 
themselves.
When the patient begins labour, heparin or LMWH 
should be withheld. Following delivery, subcuta­
neous heparin or LMWH should be started again in 
the same dose or a coumarin derivative should be 
given orally for 4 to 6 weeks postpartum.
7. Summary
An initial course of heparin or LMWH is regarded 
as the treatment of choice for patients with DVT. SH 
acts as an immediate inhibitor of several steps of the 
intrinsic coagulation pathway. It should be given 
intravenously with loading and maintenance doses to 
consistently prolong the APTT to between 1.5- and 
2.5-fold the control value or heparin level between 
The well-known coagulopathy of pregnancy is 0.2 and 0.4 U /m l. LMWH have better bioavailabil-
A -A
6. Pregnancy
characterized by an increased concentration of circu­ ity after subcutaneous administration, have a longer
lating dotting factors, more rapid turnover of platelets half-life, and show higher and more predictable anti-
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>agulant activity, probably because there is less 
)n-specific binding to plasma proteins. As a result 
ey can be given subcutaneously and without labo- 
.tory control, using a dose that is determined by 
jdyweight. Also, because the constraints of contin- 
Dus infusion are lacking, early mobilization is pos- 
ble. Because of these multiple advantages of 
MWH they will replace SH in the future and home 
eatment with LMWH of selected patients then 
îems feasible.
The currently accepted approach is to start with 
H or LMWH therapy and oral anticoagulant ther- 
py together at the time of diagnosis. The course of 
H or LMWH must take at least 5 days, provided 
iat INR is in the therapeutic range on 2 consecutive 
ays. This short-course regimen cannot yet be rec- 
mmended for patients with more extensive disease 
ike iliac vein DVT, so this should be evaluated 
urther. OAT should be continued for at least 3 
nonths to prolong the prothrombin time to an INR 
>f 2-3. However, the optimal duration as well as the 
>ptimal intensity still have to be determined. When 
)ral anticoagulants are either contraindicated or in- 
:onvenient, SH or LMWH can be used at the mid- 
iosing interval. The role of anti-platelet treatment is 
lot yet established and should be compared with 
coumarin therapy in the future.
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